MEDIGEN VACCINE BIOLOGICS CORPORATION
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Cell culture is one of the most important technologies for producing biopharma products today.
MVC specializes in cell culture processes and operates Taiwan's first large-scale PIC/S GMP cell culture manufacturing plant to meet the needs for mass producti
MVC specializes in cell culture processes and operates Taiwan's first large-scale PIC/S GMP cell culture manufacturing plant to meet the needs for mass producti
Founded Year
2012
Unified Business No.
53943057
Status
Active
Number of Employees
0
Total Paid-in
Capital
3,287,490,500 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
OTC listing(2018)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
MVC is a biopharmaceutical company focusing on the development and mass production of vaccines and biologics. We have PIC/S GMP certified cell culture commercial mass production capabilities, and target global and regional infectious diseases to develop novel vaccines and affordable biosimilar drugs via international alliances.
We are based in Taiwan and human health is our priority. Since MVC was established, we are dedicated to developing countermeasures for the prevention and treatment of emerging infectious diseases such as COVID-19, Enterovirus A71, Dengue, and Influenza vaccines. Our achievements to date prove that our products and technologies deliver.
We believe the right to health is a fundamental part of our human rights and also the foundation of global development. Vaccines and biologics are key strategies to approach the goal. We are continuing to provide safe, effective, and qualified medical products and aim to become the R&D and mass production hub in the Asia-Pacific region. We are introducing our products to the world to protect people from the threat of numerous diseases.
We are based in Taiwan and human health is our priority. Since MVC was established, we are dedicated to developing countermeasures for the prevention and treatment of emerging infectious diseases such as COVID-19, Enterovirus A71, Dengue, and Influenza vaccines. Our achievements to date prove that our products and technologies deliver.
We believe the right to health is a fundamental part of our human rights and also the foundation of global development. Vaccines and biologics are key strategies to approach the goal. We are continuing to provide safe, effective, and qualified medical products and aim to become the R&D and mass production hub in the Asia-Pacific region. We are introducing our products to the world to protect people from the threat of numerous diseases.
